Csl Limited

Other

The University of New South Wales

The Univ. of New South Wales

Christopher Vincent Doidge

Adrian Lee

Stuart L Hazell

Elizabeth Ann Webb

Flona J Radcliff

Ian George Barr

Michael John Kleinig

Linda J Rothel

Fiona Jane Radcliff

Elizabeth Pietrzykowski

Fiona Jane Buck

Phillip Sutton

Charles Alexander Quinn

Dianna Margaret Hocking

Fona J Radcliff

An isolated polypeptide and immunogenic fragments thereof are described together with their variants and derivatives as novel immunogenic agents for treating or preventinginfection in a mammalian host. The polypeptide comprises a C-terminal portion of acatalase, which portion lacks significant amino acid sequence identity with human catalase, wherein the polypeptide is other than full-lengthcatalase.

Polypeptide fragments comprising c terminal portion of helicobacter catalase

Protective Helicobacter antigens, especially H. pylori antigens, and the use of these antigens for the treatment of or prevention of, gastroduodenal disease associated with H. pylori infection.

Protective helicobacter antigens

An antigenic preparation for use in the treatment or prevention of Helicobacter infection in a mammalian host, comprises the lipopolysaccharide (LPS) of Helicobacter bacteria, particularly the LPS of or , or an immunogenic fragment thereof.

Antigenic preparation for treatment or prevention of helicobacter infection

An antigenic preparation for use in the treatment or prevention of Helicobacter infection in a mammalian host, comprises the catalase enzyme of Helicobacter bacteria, particularly the catalase enzyme of or , or an immunogenic fragment thereof.

Treatment and prevention of helicobacter infection

An antigenic preparation for use in the treatment of prevention of Helicobacter infection in a mammalian host, comprises the catalase enzyme of Helicobacter bacterial, particularly the catalase enzyme of or , or an immunogenic fragment thereof.

The application discloses a method for the treatment of Heliobacter infection in a mammalian host, which comprises administration to said infected host of an immunologically effective amount of one or more Heliobacter antigen(s), optionally in association with a mucosal adjuvant.

Treatment of H. pylori associated gastroduodenal disease

An antigenic preparation for use in the treatment or prevention of Helicobacter infection in a mammalian host, comprises the catalase enzyme of Helicobacter bacteria, particularly the catalase enzyme of H. pylori or H. felis, or an immunogenic fragment thereof.

Growing community of inventors

Box Hill, Australia

Christopher Vincent Doidge